Business context and reporting period
Gossamer Bio, Inc. filed this Form 8-K to report a Nasdaq listing-status update. The event occurred September 25, 2026; the report was signed September 28, 2026.
Key financial metrics
This filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial results.
Material change
Nasdaq notified the company that it had regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1), and that the matter was closed. Nasdaq had previously notified the company on April 8, 2026 that it was out of compliance after its stock failed to maintain a bid price of at least $1.00 for 30 consecutive business days.
The company effected a 1-for-80 reverse stock split on September 10, 2026, and its common stock began trading on a split-adjusted basis on September 11, 2026.
Outlook, risks, and unusual items
The filing provides no financial guidance or broader outlook. The reverse stock split and the resolution of the minimum bid price issue are the principal disclosed developments; no other contingencies or unusual items are described.
Investor facts to verify
- Confirm the company’s continuing compliance with Nasdaq listing requirements.
- Review the effects of the 1-for-80 reverse stock split on share count and per-share trading.
- Consult the company’s financial filings for financial results and liquidity information not included in this 8-K.